CORE 1--TISSUE PROCUREMENT AND GENETICS

核心 1——组织采购和遗传学

• 批准号: 7286331
• 负责人: ROGER E MCLENDON
• 金额: $ 9.72万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7286331
• 关键词: biomedical facility; brain neoplasms; cancer registry /resource; cytogenetics; human therapy evaluation; human tissue; molecular biology information system; neoplasm /cancer genetics; neoplasm /cancer therapy

We hypothesize that a tissue bank organized around an integrated histologic and molecular diagnostic laboratory with all research and clinical information available from a constantly updated database is an essential element to the success of this SPORE. To test this hypothesis we propose the following 4 Specific Aims: (1) to provide DNA, RNA, and tissue from neoplastic brain as well as DNA, RNA, tissue, and serum from normal blood, brain, and other body sites to programs and investigators within the SPORE, in a manner in which they can be used for a variety of studies and techniques under the oversight of the SPORE Tissue Committee; (2) to apply an integrated tissue bank/clinical data informatics system that allows the rapid identification of patient groups based on common demographics, clinical data, tissue diagnoses, and/or imaging studies and the efficient management and analysis of data from research results and clinical outcome under the oversight of a Tissue Committee; (3) to provide molecular genetic, molecular cytogenetic, and histologie analysis of banked samples in order to detect markers of classification, grading, and therapeutic response and to translate these findings into clinical trials with all projects in this SPORE. (4) to provide qualitative and quantitative assessments at the molecular, cellular, and histologic level of markers discovered in this SPORE for the translation of these basic discoveries into clinical trials. Initially we will characterize intratumoral and intertumoral heterogeneity and the diagnostic and prognostic significance of immunoreactivity for alkylguanine transferase (AGT), for the newly identified tumor glial cell surface markers MRP3, EGFR, and EGFRvIII, for glutathione S-transferase P1 (GSTP1) and for CMV antigen, pp65, in malignant human gliomas.

我们假设，围绕综合组织学和分子诊断实验室组织的组织库，以及不断更新的数据库中提供的所有研究和临床信息，是该 SPORE 成功的基本要素。 为了检验这一假设，我们提出以下 4 个具体目标： (1) 向 SPORE 内的项目和研究人员提供来自肿瘤性大脑的 DNA、RNA 和组织，以及来自正常血液、大脑和其他身体部位的 DNA、RNA、组织和血清，以使其能够在孢子组织委员会的监督下用于各种研究和技术； (2) 应用集成的组织库/临床数据信息学系统，能够根据常见的人口统计、临床数据、组织诊断和/或影像研究快速识别患者群体，并对研究结果和数据进行有效的管理和分析。在组织委员会监督下的临床结果； (3) 对库存样本进行分子遗传学、分子细胞遗传学和组织学分析，以检测分类、分级和治疗反应的标记，并将这些发现转化为本 SPORE 中所有项目的临床试验。 (4) 在该 SPORE 中发现的标记物的分子、细胞和组织学水平上提供定性和定量评估，以便将这些基本发现转化为临床试验。首先，我们将描述肿瘤内和肿瘤间异质性以及烷基鸟嘌呤转移酶（AGT）、新鉴定的肿瘤胶质细胞表面标记物MRP3、EGFR和EGFRvIII、谷胱甘肽S-转移酶P1（GSTP1）和免疫反应性的诊断和预后意义。 CMV 抗原，pp65，存在于人类恶性神经胶质瘤中。